Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Osteoarthritis (OA) is one of the most common illness in man. The
frequency of 0A in the general population is estimated to be as great as
35% in the 30-40 year old age group and the frequency may rise to as much
as 85% in individuals greater than 70 years of age. 0A is also a
significant cause of work absenteeism and a significant cause of
disability. Furthermore, 0A represents a significant burden to the
health care system because of the extensive consultation with physicians
and the use of medication needed to treat the disease. In this proposal,
we intend to define genetic factors that contribute to 0A and
degenerative joint disease. our initial studies will concentrate on
disease present in a large New England family with both chondrocalcinosis
and severe degenerative OA. In this family, disease appears to be
inherited in an autosomal dominant fashion suggesting a strong genetic
component being responsible for the disease. Using genetic linkage
experiments, we established linkage between disease and human chromosome
8q in this family. Our specific aims are designed to use genetic linkage
experiments to further refine the location of the gene for disease in
this family. We will then obtain DNA clones for the candidate region and
search for genes that, when defective, cause disease. We will then
sequence the defective gene to determine the exact cause of disease. We
will then extend our findings to test the hypothesis that this gene, and
others that we may find, play important roles in common forms of 0A. In
addition, the results of this study will define the exact role these
genes play in cartilage and establish why defects in their expression
result in disease. It will also permit the exact diagnosis of the disease
and help us understand existing animal models for OA. In addition,
information derived from our work will provide the basis for developing
better animal models in which new therapies can be tested and the
pathogenesis of the disease be followed.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
25-September-1995
Project End Date
31-August-1999
Budget Start Date
25-September-1995
Budget End Date
31-August-1996
Project Funding Information for 1995
Total Funding
$201,007
Direct Costs
$120,810
Indirect Costs
$80,197
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$201,007
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AR043858-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AR043858-01
Patents
No Patents information available for 1R01AR043858-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AR043858-01
Clinical Studies
No Clinical Studies information available for 1R01AR043858-01
News and More
Related News Releases
No news release information available for 1R01AR043858-01
History
No Historical information available for 1R01AR043858-01
Similar Projects
No Similar Projects information available for 1R01AR043858-01